Trial Profile
Phase I Study of KN026 in HER2 Expressing Breast Cancer, Astric/Gastroesophageal Junction Cancer and Other Locally Advanced/Metastatic Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Anbenitamab (Primary)
- Indications Advanced breast cancer; Gastric cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors Alphamab Oncology
- 16 Nov 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 16 Nov 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2022.
- 16 Nov 2021 Status changed from recruiting to active, no longer recruiting.